Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2018 February;59(1) > The Journal of Cardiovascular Surgery 2018 February;59(1):51-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  GLOBAL PERSPECTIVES ON DRUG-ELUTING BALLOON TECHNOLOGY AND SCIENCE 

The Journal of Cardiovascular Surgery 2018 February;59(1):51-9

DOI: 10.23736/S0021-9509.17.10245-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

The evolving role of drug-coated balloons for the treatment of complex femoropopliteal lesions

Grigorios KOROSOGLOU 1, Michael LICHTENBERG 2, Sultan CELIK 3, Joachim ANDRASSY 4, Marianne BRODMANN 5, Martin ANDRASSY 3

1 Gesundheitszentren Rhein-Neckar Clinic, Weinheim, Germany; 2 Vascular Center, Arnsberg, Germany; 3 Fürst-Stirum Clinic, Bruchsal, Germany; 4 Department of Surgery, Munich University Hospital, Munich, Germany; 5 Department of Vascular Medicine, University of Graz, Graz, Austria


PDF


Conventional therapies for transcatheter treatment of patients with infrainguinal obstructive disease remain compromised by high restenosis rates. Drug-coated balloons (DCB) offer a novel therapeutic alternative targeting the source of neo-intimal hyperplasia, without the need for a permanent endovascular scaffold and their inherent limitations. A systematic research of the medical databases (Pubmed) has been conducted for this up-to-date review. Key words, such as “drug-coated balloons” (DCB), “drug-eluting balloon,” “in-stent-restenosis” (ISR), “de-novo stenosis,” “plain old angioplasty,” “atherectomy,” “debulking,” “superficial femoral artery,” “popliteal artery,” “above/below the knee,” and “peripheral artery disease” have been used for literature search. Furthermore, data from reviews, original contributions, randomized controlled studies, observational studies, registries and single center experiences have been considered. Overall, an increasing level of evidence supports the use of DCB for the treatment of long, complex, heavily calcified femoropopliteal non-occlusive and occlusive lesions, including failure after BM stent implantation due to ISR. However, more studies will be necessary to investigate the long-term effects of DCB-treatment in these real-world lesions.


KEY WORDS: Arterial occlusive diseases - Balloon angioplasty - Atherectomy

inizio pagina